{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:32:39Z","timestamp":1777984359639,"version":"3.51.4"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Sex Differ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long COVID (LC) is a post-infectious condition affecting millions worldwide, characterized by persistent multisystem symptoms. Females are disproportionately affected, reporting higher symptom burden, particularly neurocognitive and neurosensory complaints. While short-term immunopathology has been described, the long-term clinical course, immune dysregulation, and sex-specific underpinnings remain poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 34 participants experiencing persisting symptoms from 9\u00a0months to 5\u00a0years post-SARS-CoV-2 infection, alongside 26 SARS-CoV-2\u2013infected controls without symptoms. Clinical assessments, symptom inventories, comorbidity analysis, and work capacity evaluation were performed. Immune profiling included flow cytometry of CD4\u207a and CD8\u207a T cells, NK cells, and B cells, as well as quantification of plasma cytokines, soluble factors, and cytotoxic molecules, analyzed in a sex-disaggregated manner.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Females with LC exhibited higher symptom burden, particularly persistent fatigue, neurocognitive and neurosensory complaints, which increased with age and tended to increase with disease duration, whereas males showed no clear age- or duration-related patterns. Comorbidities, especially affecting endocrine, metabolic, and circulatory systems, were more frequent in females and aligned with symptom severity. Immune profiling revealed subtle but sex-specific differences: females had reduced CD8\u207a T cell cytotoxic profile, lower NKG2D and granzyme K expression, increased sCD40L and sFAS, and decreased perforin, whereas males displayed elevated TNF-\u03b1. NK cell function, B cells, and humoral immunity remained largely intact. Over half of participants reported functional impairments affecting work capacity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Even though our cohort is small it suggests that prolonged LC is characterized by sex-specific differences in symptom burden and immune profiles. Reduced cytotoxic CD8\u207a T cell profile in females may contribute to viral persistence and neurological symptoms, whereas elevated inflammatory markers in males suggest distinct immune pathways. These findings highlight the need for sex- and duration-specific management strategies, the identification of biomarkers, and the development of personalized therapies targeting specific LC endotypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13293-026-00825-9","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T04:24:49Z","timestamp":1769487889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term sex differences in symptoms and immune profile in long COVID"],"prefix":"10.1186","volume":"17","author":[{"given":"Jos\u00e9","family":"Feliz","sequence":"first","affiliation":[]},{"given":"Juliana","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Carolina","family":"Cabedo","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Brito","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Gamas","sequence":"additional","affiliation":[]},{"given":"Maria In\u00eas","family":"Neves","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Soares","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"825_CR1","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/S1473-3099(21)00703-9","volume":"22","author":"JB Soriano","year":"2022","unstructured":"Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis Elsevier Ltd. 2022;22:e102\u20137.","journal-title":"Lancet Infect Dis Elsevier Ltd"},{"key":"825_CR2","first-page":"1","volume":"13","author":"E Paradowska-Nowakowska","year":"2023","unstructured":"Paradowska-Nowakowska E, \u0141oboda D, Go\u0142ba KS, Sarecka-Hujar B. Long COVID-19 syndrome severity according to sex, time from the onset of the disease, and exercise capacity\u2014The results of a cross-sectional study. Life MDPI. 2023;13:1\u201317.","journal-title":"Life MDPI"},{"key":"825_CR3","first-page":"1","volume":"11","author":"G Maglietta","year":"2022","unstructured":"Maglietta G, Diodati F, Puntoni M, Lazzarelli S, Marcomini B, Patrizi L, et al. Prognostic factors for post-COVID-19 syndrome: A systematic review and meta-analysis. J Clin Med MDPI. 2022;11:1\u20135.","journal-title":"J Clin Med MDPI"},{"key":"825_CR4","first-page":"1","volume":"11","author":"KI Notarte","year":"2022","unstructured":"Notarte KI, de Oliveira MHS, Peligro PJ, Velasco JV, Macaranas I, Ver AT, et al. Age, sex and previous comorbidities as risk factors not associated with SARS-CoV-2 infection for long COVID-19: a systematic review and meta-Analysis. J Clin Med MDPI. 2022;11:1\u201324.","journal-title":"J Clin Med MDPI"},{"key":"825_CR5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41590-021-01104-y","volume":"23","author":"S Mehandru","year":"2022","unstructured":"Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23:194\u2013202.","journal-title":"Nat Immunol"},{"key":"825_CR6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133\u201346.","journal-title":"Nat Rev Microbiol"},{"key":"825_CR7","first-page":"1","volume":"14","author":"CE Hastie","year":"2023","unstructured":"Hastie CE, Lowe DJ, McAuley A, Mills NL, Winter AJ, Black C, et al. True prevalence of long-COVID in a nationwide, population cohort study. Nat Commun. 2023;14:1\u20136.","journal-title":"Nat Commun"},{"key":"825_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjgh-2021-005427","volume":"6","author":"M Michelen","year":"2021","unstructured":"Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long COVID: A living systematic review. BMJ Glob Health. 2021;6:1\u201312.","journal-title":"BMJ Glob Health"},{"key":"825_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2021.750378","volume":"8","author":"LD Hayes","year":"2021","unstructured":"Hayes LD, Ingram J, Sculthorpe NF. More than 100 persistent symptoms of SARS-CoV-2 (Long COVID): a scoping review. Front Med. 2021;8:1\u201321.","journal-title":"Front Med."},{"key":"825_CR10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","volume":"26","author":"A Gupta","year":"2020","unstructured":"Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26:1017\u201332.","journal-title":"Nat Med"},{"key":"825_CR11","first-page":"1","volume":"372","author":"D Ayoubkhani","year":"2021","unstructured":"Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: Retrospective cohort study. The BMJ. 2021;372:1\u201310.","journal-title":"The BMJ"},{"key":"825_CR12","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-022-01909-w","volume":"28","author":"A Subramanian","year":"2022","unstructured":"Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706\u201314.","journal-title":"Nat Med"},{"key":"825_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom14070835","volume":"14","author":"R Ashmawy","year":"2024","unstructured":"Ashmawy R, Hammouda EA, El-Maradny YA, Aboelsaad I, Hussein M, Uversky VN, et al. Interplay between comorbidities and long COVID: challenges and multidisciplinary approaches. Biomolecules. 2024;14:1\u201324.","journal-title":"Biomolecules"},{"key":"825_CR14","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1016\/j.bja.2020.12.007","volume":"126","author":"M Taboada","year":"2021","unstructured":"Taboada M, Moreno E, Carinena A, Rey T, Pita-Romero R, Leal S, et al. Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients. Br J Anaesth. 2021;126:e110\u20133.","journal-title":"Br J Anaesth"},{"key":"825_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0240784","volume":"15","author":"L Townsend","year":"2020","unstructured":"Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15:1\u201312.","journal-title":"PLoS One"},{"key":"825_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nmni.2021.100838","volume":"40","author":"A Mannan","year":"2021","unstructured":"Mannan A, Mehedi HMH, Chy NUHA, Qayum MO, Akter F, Rob MA, et al. A multi-centre, cross-sectional study on coronavirus disease 2019 in Bangladesh: clinical epidemiology and short-term outcomes in recovered individuals. New Microbes New Infect. 2021;40:1\u20139.","journal-title":"New Microbes New Infect"},{"key":"825_CR17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cmi.2020.09.023","volume":"27","author":"Q Xiong","year":"2021","unstructured":"Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27:89\u201395.","journal-title":"Clin Microbiol Infect"},{"key":"825_CR18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-022-01689-3","volume":"28","author":"Y Xie","year":"2022","unstructured":"Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583\u201390.","journal-title":"Nat Med"},{"key":"825_CR19","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/infdis\/jiac136","volume":"226","author":"C Chen","year":"2022","unstructured":"Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226:1593\u2013607.","journal-title":"J Infect Dis"},{"key":"825_CR20","first-page":"1","volume":"2","author":"MS Woo","year":"2020","unstructured":"Woo MS, Malsy J, P\u00f6ttgen J, Seddiq Zai S, Ufer F, Hadjilaou A, et al. Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun. 2020;2:1\u20139.","journal-title":"Brain Commun"},{"key":"825_CR21","first-page":"1","volume":"372","author":"W Shah","year":"2021","unstructured":"Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:1\u20134.","journal-title":"BMJ"},{"key":"825_CR22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41586-023-06651-y","volume":"623","author":"J Klein","year":"2023","unstructured":"Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623:139\u201348.","journal-title":"Nature"},{"key":"825_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1004511","volume":"22","author":"RS Peter","year":"2025","unstructured":"Peter RS, Nieters A, G\u00f6pel S, Merle U, Steinacker JM, Deibert P, et al. Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19\/ post-COVID-19 syndrome in the second year after acute infection: A population-based, nested case-control study. PLoS Med. 2025;22:1\u201334.","journal-title":"PLoS Med"},{"key":"825_CR24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1473-3099(23)00053-1","volume":"23","author":"D Putrino","year":"2023","unstructured":"Putrino D, Iwasaki A. Why we need a deeper understanding of the pathophysiology of long COVID. Lancet Infect Dis. 2023;23:393\u20135.","journal-title":"Lancet Infect Dis"},{"key":"825_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofae027","volume":"11","author":"ZO Demko","year":"2024","unstructured":"Demko ZO, Yu T, Mullapudi SK, Heslin MGV, Dorsey CA, Payton CB, et al. Two-Year longitudinal study reveals that long COVID symptoms peak and quality of life nadirs at 6\u201312 months postinfection. Open Forum Infect Dis. 2024;11:1\u20138.","journal-title":"Open Forum Infect Dis"},{"key":"825_CR26","first-page":"1","volume":"16","author":"G Joseph","year":"2024","unstructured":"Joseph G, Margalit I, Weiss-Ottolenghi Y, Rubin C, Murad H, Gardner RC, et al. Persistence of long COVID symptoms two years after SARS-CoV-2 infection: a prospective longitudinal cohort study. Viruses. 2024;16:1\u201311.","journal-title":"Viruses"},{"key":"825_CR27","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/cid\/ciab611","volume":"74","author":"J Seeble","year":"2022","unstructured":"Seeble J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin Infect Dis. 2022;74:1191\u20138.","journal-title":"Clin Infect Dis"},{"key":"825_CR28","first-page":"1","volume":"38","author":"HE Davis","year":"2021","unstructured":"Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re\u2019em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinMed. 2021;38:1\u201319.","journal-title":"EClinMed"},{"key":"825_CR29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJMoa2403211","volume":"391","author":"Y Xie","year":"2024","unstructured":"Xie Y, Choi T, Al-Aly Z. Postacute sequelae of SARS-CoV-2 infection in the Pre-Delta, delta, and omicron eras. New England J Med. 2024;391:515\u201325.","journal-title":"New England J Med"},{"key":"825_CR30","first-page":"1","volume":"13","author":"VT Tran","year":"2022","unstructured":"Tran VT, Porcher R, Pane I, Ravaud P. Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat Commun. 2022;13:1\u20136.","journal-title":"Nat Commun"},{"key":"825_CR31","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S2215-0366(22)00260-7","volume":"9","author":"M Taquet","year":"2022","unstructured":"Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatr. 2022;9:815\u201327.","journal-title":"Lancet Psychiatr"},{"key":"825_CR32","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41591-021-01292-y","volume":"27","author":"CH Sudre","year":"2021","unstructured":"Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626\u201331.","journal-title":"Nat Med"},{"key":"825_CR33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0140-6736(24)01136-X","volume":"404","author":"T Greenhalgh","year":"2024","unstructured":"Greenhalgh T, Sivan M, Perlowski A, Nikolich J. Long COVID: a clinical update. The Lancet. 2024;404:707\u201324.","journal-title":"The Lancet."},{"key":"825_CR34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41591-022-01810-6","volume":"28","author":"J Choutka","year":"2022","unstructured":"Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28:911\u201323.","journal-title":"Nat Med"},{"key":"825_CR35","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2022.100995","volume":"66","author":"N Thomas","year":"2022","unstructured":"Thomas N, Gurvich C, Huang K, Gooley PR, Armstrong CW. The underlying sex differences in neuroendocrine adaptations relevant to Myalgic Encephalomyelitis Chronic Fatigue Syndrome. Front Neuroendocrinol. 2022;66:100995.","journal-title":"Front Neuroendocrinol"},{"key":"825_CR36","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199\u2013207.","journal-title":"N Engl J Med."},{"key":"825_CR37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395:507\u201313.","journal-title":"The Lancet"},{"key":"825_CR38","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41577-020-0348-8","volume":"20","author":"EP Scully","year":"2020","unstructured":"Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20:442\u20137.","journal-title":"Nat Rev Immunol."},{"key":"825_CR39","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430\u20136.","journal-title":"Nature."},{"key":"825_CR40","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1080\/03007995.2022.2081454","volume":"38","author":"SV Sylvester","year":"2022","unstructured":"Sylvester SV, Rusu R, Chan B, Bellows M, O\u2019Keefe C, Nicholson S. Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review. Curr Med Res Opin. 2022;38:1391\u20139.","journal-title":"Curr Med Res Opin."},{"key":"825_CR41","doi-asserted-by":"crossref","first-page":"eadr1032","DOI":"10.1126\/scitranslmed.adr1032","volume":"16","author":"RE Hamlin","year":"2025","unstructured":"Hamlin RE, Pienkos SM, Chan L, Stabile MA, Pinedo K, Rao M, et al. Sex differences and immune correlates of Long Covid development, symptom persistence, and resolution. Sci Transl Med. 2025;16:eadr1032.","journal-title":"Sci Transl Med."},{"key":"825_CR42","doi-asserted-by":"crossref","unstructured":"Silva J, Takahashi T, Wood J, Lu P, Tabachnikova A, Gehlhausen JR, et al. 2024 Sex differences in symptomatology and immune profiles of Long COVID. medRxiv.","DOI":"10.1101\/2024.02.29.24303568"},{"key":"825_CR43","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1080\/07853890.2022.2076901","volume":"54","author":"D Castanares-Zapatero","year":"2022","unstructured":"Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54:1473\u201387.","journal-title":"Ann Med."},{"key":"825_CR44","first-page":"1","volume":"61","author":"MN Stefania","year":"2025","unstructured":"Stefania MN, Toma C, Bondor CI, Maria RV, Florin P, Adina MM. Long COVID and lung involvement: a one-year longitudinal, real-life study. Medicina (B Aires). 2025;61:1\u201311.","journal-title":"Medicina (B Aires)"},{"key":"825_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-025-10805-w","volume":"25","author":"A Santoro","year":"2025","unstructured":"Santoro A, Bai F, Greco MF, Rovito R, Sala M, Borghi L, et al. Short and long-term trajectories of the post COVID-19 condition: Results from the EuCARE POSTCOVID study. BMC Infect Dis. 2025;25:1\u201310.","journal-title":"BMC Infect Dis"},{"key":"825_CR46","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/s41591-023-02521-2","volume":"29","author":"B Bowe","year":"2023","unstructured":"Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. 2023;29:2347\u201357.","journal-title":"Nat Med"},{"key":"825_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-025-03974-7","volume":"23","author":"M Kogevinas","year":"2025","unstructured":"Kogevinas M, Karachaliou M, Espinosa A, Iraola-Guzm\u00e1n S, Casta\u00f1o-Vinyals G, Delgado-Ortiz L, et al. Risk, determinants, and persistence of long-COVID in a population-based cohort study in Catalonia. BMC Med. 2025;23:1\u201313.","journal-title":"BMC Med"},{"key":"825_CR48","first-page":"1","volume":"2","author":"J Gon\u00e7alves","year":"2021","unstructured":"Gon\u00e7alves J, Juliano AM, Charepe N, Alenquer M, Athayde D, Ferreira F, et al. Secretory IgA and T cells targeting SARS-CoV-2 spike protein are transferred to the breastmilk upon mRNA vaccination. Cell Rep Med. 2021;2:1\u201314.","journal-title":"Cell Rep Med"},{"key":"825_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.167140","volume":"8","author":"J Gon\u00e7alves","year":"2023","unstructured":"Gon\u00e7alves J, Melro M, Alenquer M, Ara\u00fajo C, Castro-Neves J, Amaral-Silva D, et al. Balance between maternal antiviral response and placental transfer of protection in gestational SARS-CoV-2 infection. JCI Insight. 2023;8:1\u201318.","journal-title":"JCI Insight"},{"key":"825_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-021-02659-0","volume":"4","author":"D Amaral-Silva","year":"2021","unstructured":"Amaral-Silva D, Gon\u00e7alves R, Torr\u00e3o RC, Torres R, Falc\u00e3o S, Gon\u00e7alves MJ, et al. Direct tissue-sensing reprograms TLR4+ Tfh-like cells inflammatory profile in the joints of rheumatoid arthritis patients. Commun Biol. 2021;4:1\u201316.","journal-title":"Commun Biol."},{"key":"825_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2020.603996","volume":"7","author":"J Gon\u00e7alves","year":"2020","unstructured":"Gon\u00e7alves J, Sousa RL, Jacinto MJ, Silva DA, Paula F, Sousa R, et al. Evaluating SARS-CoV-2 seroconversion following relieve of confinement measures. Front Med. 2020;7:1\u201310.","journal-title":"Front Med"},{"key":"825_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cpmc.100","volume":"57","author":"D Stadlbauer","year":"2020","unstructured":"Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr Protoc Microbiol. 2020;57:1\u201315.","journal-title":"Curr Protoc Microbiol"},{"key":"825_CR53","first-page":"19","volume":"1","author":"M Tomczak","year":"2014","unstructured":"Tomczak M, Tomczak E. The need to report effect size estimates revisited. An overview of some recommended measures of effect size. Trends Sport Sci. 2014;1:19\u201325.","journal-title":"Trends Sport Sci"},{"key":"825_CR54","unstructured":"Cohen J. 1988 Statistical Power Analysis for the Behavioral Sciences Second Edition."},{"key":"825_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jiph.2024.102562","volume":"17","author":"T Fuller","year":"2024","unstructured":"Fuller T, Flores Mamani R, Ferreira Pinto Santos H, Melo Esp\u00edndola O, Guaraldo L, Lopes Melo C, et al. Sex, vaccination status, and comorbidities influence long COVID persistence. J Infect Public Health. 2024;17:1\u20137.","journal-title":"J Infect Public Health."},{"key":"825_CR56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2025.107912","volume":"156","author":"MS Berends","year":"2025","unstructured":"Berends MS, Homburg M, Kupers T, Meijer EN, Bos I, Verheij R, et al. Impact of pre-existing comorbidities and multimorbidities, demography and viral variants on post-acute sequelae of COVID-19 (\u2018Long COVID\u2019) in Dutch primary care: A retrospective cohort study. Int J Infect Dis. 2025;156:1\u20138.","journal-title":"Int J Infect Dis"},{"key":"825_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/diagnostics12102502","volume":"12","author":"R Cioboata","year":"2022","unstructured":"Cioboata R, Nicolosu D, Streba CT, Vasile CM, Olteanu M, Nemes A, et al. Post-COVID-19 syndrome based on disease form and associated comorbidities. Diagnostics. 2022;12:1\u201310.","journal-title":"Diagnostics"},{"key":"825_CR58","doi-asserted-by":"crossref","unstructured":"O\u2019Brien KK, Brown DA, McDuff K, St. Clair-Sullivan N, Solomon P, Chan Carusone S, et al. 2023 Conceptualising the episodic nature of disability among adults living with Long COVID: a qualitative study. BMJ Glob Health. 8:1\u201313.","DOI":"10.1136\/bmjgh-2022-011276"},{"key":"825_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7189\/jogh.15.04006","volume":"15","author":"R Owen","year":"2025","unstructured":"Owen R, Ashton REM, Bewick T, Copeland RJ, Ferraro FV, Kennerley C, et al. Profiling the persistent and episodic nature of long COVID symptoms and the impact on quality of life and functional status: a cohort observation study. J Glob Health. 2025;15:1\u20137.","journal-title":"J Glob Health"},{"key":"825_CR60","doi-asserted-by":"crossref","first-page":"618","DOI":"10.20344\/amp.19566","volume":"36","author":"AM Oliveira","year":"2023","unstructured":"Oliveira AM, Coelho CF, Louren\u00e7o F, Pinto IC, Atab\u00e3o J, Cabrita R, et al. Long COVID symptoms in non-hospitalised patients: a retrospective study. Acta Med Port. 2023;36:618\u201330.","journal-title":"Acta Med Port"},{"key":"825_CR61","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","volume":"27","author":"EM Bange","year":"2021","unstructured":"Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27:1280\u20139.","journal-title":"Nat Med"},{"key":"825_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2021.109414","volume":"36","author":"J Neidleman","year":"2021","unstructured":"Neidleman J, Luo X, George AF, McGregor M, Yang J, Yun C, et al. Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Cell Rep. 2021;36:1\u201324.","journal-title":"Cell Rep."},{"key":"825_CR63","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41586-022-04865-0","volume":"607","author":"RK Suryawanshi","year":"2022","unstructured":"Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, et al. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature. 2022;607:351\u20135.","journal-title":"Nature"},{"key":"825_CR64","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.4049\/jimmunol.2100465","volume":"207","author":"T Ma","year":"2021","unstructured":"Ma T, Ryu H, McGregor M, Babcock B, Neidleman J, Xie G, et al. Protracted yet coordinated differentiation of long-lived SARS-CoV-2-SpecificCD8+ T cells during convalescence. J Immunol. 2021;207:1344\u201356.","journal-title":"J Immunol"},{"key":"825_CR65","first-page":"1","volume":"3","author":"K Kedzierska","year":"2022","unstructured":"Kedzierska K, Thomas PG. Count on us: T cells in SARS-CoV-2 infection and vaccination. Cell Rep Med. 2022;3:1\u20137.","journal-title":"Cell Rep Med"},{"key":"825_CR66","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41590-023-01724-6","volume":"25","author":"K Yin","year":"2024","unstructured":"Yin K, Peluso MJ, Luo X, Thomas R, Shin MG, Neidleman J, et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat Immunol. 2024;25:218\u201325.","journal-title":"Nat Immunol"},{"key":"825_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1073\/pnas.2411428121","volume":"121","author":"LC Rowntree","year":"2024","unstructured":"Rowntree LC, Audsley J, Allen LF, McQuilten HA, Hagen RR, Chaurasia P, et al. SARS-CoV-2-specific CD8+ T cells from people with long COVID establish and maintain effector phenotype and key TCR signatures over 2 years. Proc Natl Acad Sci U S A. 2024;121:1\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"825_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.848886","volume":"13","author":"M Gal\u00e1n","year":"2022","unstructured":"Gal\u00e1n M, Vig\u00f3n L, Fuertes D, Murciano-Ant\u00f3n MA, Casado-Fern\u00e1ndez G, Dom\u00ednguez-Mateos S, et al. Persistent overactive cytotoxic immune response in a Spanish cohort of individuals with long-COVID: identification of diagnostic biomarkers. Front Immunol. 2022;13:1\u201315.","journal-title":"Front Immunol"},{"key":"825_CR69","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/jim-2021-002051","volume":"70","author":"P Glynne","year":"2022","unstructured":"Glynne P, Tahmasebi N, Gant V, Gupta R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Invest Med. 2022;70:61\u20137.","journal-title":"J Invest Med"},{"key":"825_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-37368-1","volume":"14","author":"A Santa Cruz","year":"2023","unstructured":"Santa Cruz A, Mendes-Frias A, Azarias-da-Silva M, Andr\u00e9 S, Oliveira AI, Pires O, et al. Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8+\u03b27 integrin+ T cells and anti-SARS-CoV-2 IgA response. Nat Commun. 2023;14:1\u201314.","journal-title":"Nat Commun"},{"key":"825_CR71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2025.110502","volume":"277","author":"K Renner","year":"2025","unstructured":"Renner K, Stauffenberg F, Paulus M, Neumayer S, Winter-K\u00f6hler F, Buchtler S, et al. Hyper-reactivity of CD8+ T cells and high expression of IL-3 correlates with occurrence and severity of Long-COVID. Clin Immunol. 2025;277:1\u201311.","journal-title":"Clin Immunol"},{"key":"825_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-025-11470-4","volume":"15","author":"JC Durieux","year":"2025","unstructured":"Durieux JC, Koberssy Z, Daher J, Baissary J, Abboud M, Atieh O, et al. Sex differences in inflammation and markers of gut integrity in long COVID. Sci Rep. 2025;15:1\u20139.","journal-title":"Sci Rep"},{"key":"825_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI188182","volume":"135","author":"T Tsao","year":"2025","unstructured":"Tsao T, Buck AM, Grimbert L, LaFranchi BH, Poblano BA, Fehrman EA, et al. Long COVID is associated with lower percentages of mature, cytotoxic NK cell phenotypes. J Clin Invest. 2025;135:1\u20134.","journal-title":"J Clin Invest"},{"key":"825_CR74","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijid.2022.07.053","volume":"123","author":"AMD Navaratnam","year":"2022","unstructured":"Navaratnam AMD, Shrotri M, Nguyen V, Braithwaite I, Beale S, Byrne TE, et al. Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort. Int J Infect Dis. 2022;123:104\u201311.","journal-title":"Int J Infect Dis"},{"key":"825_CR75","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(21)00575-4","volume":"397","author":"CH Hansen","year":"2021","unstructured":"Hansen CH, Michlmayr D, Gubbels SM, M\u00f8lbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021;397:1204\u201312.","journal-title":"Lancet"},{"key":"825_CR76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cimb47040245","volume":"47","author":"ZR Korobova","year":"2025","unstructured":"Korobova ZR, Arsentieva NA, Liubimova NE, Batsunov OK, Butenko AA, Kokoeva AE, et al. B Cell dynamics and transitional B Cells in long COVID. Curr Issues Mol Biol. 2025;47:1.","journal-title":"Curr Issues Mol Biol."},{"key":"825_CR77","first-page":"1","volume":"26","author":"J Flores-Gonzalez","year":"2025","unstructured":"Flores-Gonzalez J, Buendia-Roldan I, T\u00e9llez-Quijada F, Pe\u00f1a-Bates C, Ram\u00f3n-Luing LA, Castorena-Maldonado A, et al. Altered immune surveillance of B and T cells in patients with persistent residual lung abnormalities 12 months after severe COVID-19. Respir Res. 2025;26:1\u201312.","journal-title":"Respir Res"},{"key":"825_CR78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-40460-1","volume":"14","author":"DM Altmann","year":"2023","unstructured":"Altmann DM, Reynolds CJ, Joy G, Otter AD, Gibbons JM, Pade C, et al. Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity. Nat Commun. 2023;14:1\u20139.","journal-title":"Nat Commun"},{"key":"825_CR79","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1016\/j.cell.2024.07.054","volume":"187","author":"MJ Peluso","year":"2024","unstructured":"Peluso MJ, Deeks SG. Mechanisms of long COVID and the path toward therapeutics. Cell. 2024;187:5500\u201329.","journal-title":"Cell."},{"key":"825_CR80","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41590-024-01778-0","volume":"25","author":"F Liew","year":"2024","unstructured":"Liew F, Efstathiou C, Fontanella S, Richardson M, Saunders R, Swieboda D, et al. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nat Immunol. 2024;25:607\u201321.","journal-title":"Nat Immunol"},{"key":"825_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-38682-4","volume":"14","author":"A Talla","year":"2023","unstructured":"Talla A, Vasaikar SV, Szeto GL, Lemos MP, Czartoski JL, MacMillan H, et al. Persistent serum protein signatures define an inflammatory subcategory of long COVID. Nat Commun. 2023;14:1\u201316.","journal-title":"Nat Commun"},{"key":"825_CR82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-40012-7","volume":"14","author":"MC Woodruff","year":"2023","unstructured":"Woodruff MC, Bonham KS, Anam FA, Walker TA, Faliti CE, Ishii Y, et al. Chronic inflammation, neutrophil activity, and autoreactivity splits long COVID. Nat Commun. 2023;14:1\u201313.","journal-title":"Nat Commun"},{"key":"825_CR83","first-page":"1","volume":"15","author":"S Saito","year":"2024","unstructured":"Saito S, Shahbaz S, Luo X, Osman M, Redmond D, Cohen Tervaert JW, et al. Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome. Front Immunol. 2024;15:1\u201316.","journal-title":"Front Immunol"},{"key":"825_CR84","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/infdis\/jiab490","volume":"224","author":"MJ Peluso","year":"2021","unstructured":"Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224:1839\u201348.","journal-title":"J Infect Dis"},{"key":"825_CR85","first-page":"1","volume":"10","author":"B Sun","year":"2021","unstructured":"Sun B, Tang N, Peluso MJ, Iyer NS, Torres L, Donatelli JL, et al. Characterization and biomarker analyses of Post-COVID-19 complications and neurological manifestations. Cells. 2021;10:1\u201317.","journal-title":"Cells"},{"key":"825_CR86","first-page":"1","volume":"3","author":"C Schulthei\u00df","year":"2022","unstructured":"Schulthei\u00df C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, et al. The IL-1\u03b2, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. 2022;3:1\u201316.","journal-title":"Cell Rep Med"},{"key":"825_CR87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.157053","volume":"7","author":"MS Durstenfeld","year":"2022","unstructured":"Durstenfeld MS, Peluso MJ, Kelly JD, Win S, Swaminathan S, Li D, et al. Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight. 2022;7:1\u201318.","journal-title":"JCI Insight."},{"key":"825_CR88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep24715","volume":"6","author":"C Aloui","year":"2016","unstructured":"Aloui C, Prigent A, Tariket S, Sut C, Fagan J, Cognasse F, et al. Levels of human platelet-derived soluble CD40 ligand depend on haplotypes of CD40LG-CD40-ITGA2. Sci Rep. 2016;6:1\u20137.","journal-title":"Sci Rep"},{"key":"825_CR89","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1161\/hc4401.099447","volume":"104","author":"U Sch\u00f6nbeck","year":"2001","unstructured":"Sch\u00f6nbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266\u20138.","journal-title":"Circulation"},{"key":"825_CR90","doi-asserted-by":"crossref","first-page":"947401","DOI":"10.3389\/fimmu.2022.947401","volume":"13","author":"K Saleki","year":"2022","unstructured":"Saleki K, Shirzad M, Javanian M, Mohammadkhani S, Alijani MH, Miri N, et al. Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients. Front Immunol. 2022;13:947401.","journal-title":"Front Immunol."},{"key":"825_CR91","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/d41586-021-03619-8","volume":"600","author":"E Callaway","year":"2021","unstructured":"Callaway E. Beyond omicron: what\u2019s next for SARS-CoV-2 evolution. Nature. 2021;600:204\u20137.","journal-title":"Nature"},{"key":"825_CR92","unstructured":"Office for National Statistics: Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK 30 March 2023. 2023 [cited 2025 Aug 13]."},{"key":"825_CR93","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s40121-021-00484-w","volume":"10","author":"M Scherlinger","year":"2021","unstructured":"Scherlinger M, Felten R, Gallais F, Nazon C, Chatelus E, Pijnenburg L, et al. Refining \u201cLong-COVID\u201d by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 infection. Infect Dis Ther Adis. 2021;10:1747\u201363.","journal-title":"Infect Dis Ther Adis"},{"key":"825_CR94","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s13365-022-01079-y","volume":"28","author":"R Hadad","year":"2022","unstructured":"Hadad R, Khoury J, Stanger C, Fisher T, Schneer S, Ben-Hayun R, et al. Cognitive dysfunction following COVID-19 infection. J Neurovirol. 2022;28:430\u20137.","journal-title":"J Neurovirol."},{"key":"825_CR95","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.reuma.2015.05.007","volume":"12","author":"M Faro","year":"2016","unstructured":"Faro M, S\u00e0ez-Franc\u00e1s N, Castro-Marrero J, Aliste L, Fern\u00e1ndez De Sevilla T, Alegre J. Gender differences in chronic fatigue syndrome. Reumatol Clin. 2016;12:72\u20137.","journal-title":"Reumatol Clin"},{"key":"825_CR96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2024.106297","volume":"89","author":"A Dehlia","year":"2024","unstructured":"Dehlia A, Guthridge MA. The persistence of myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) after SARS-CoV-2 infection: A systematic review and meta-analysis. J Infect. 2024;89:1\u20139.","journal-title":"J Infect"},{"key":"825_CR97","first-page":"1","volume":"9","author":"ME Schmidt","year":"2018","unstructured":"Schmidt ME, Varga SM. The CD8 T cell response to respiratory virus infections. Front Immunol. 2018;9:1\u201312.","journal-title":"Front Immunol"},{"key":"825_CR98","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163669","author":"MJ Peluso","year":"2023","unstructured":"Peluso MJ, Deveau T-M, Munter SE, Ryder D, Buck A, Beck-Engeser G, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023. https:\/\/doi.org\/10.1172\/JCI163669.","journal-title":"J Clin Invest"},{"key":"825_CR99","first-page":"1","volume":"95","author":"SW Huang","year":"2023","unstructured":"Huang SW, Yeh WB, Chen HY, Yong SB. Long-term risk of herpes zoster following COVID-19: a retrospective cohort study of 2 442 686 patients. J Med Virol. 2023;95:1\u20131.","journal-title":"J Med Virol"},{"key":"825_CR100","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4049\/jimmunol.1300670","volume":"191","author":"FM Wensveen","year":"2013","unstructured":"Wensveen FM, Lenarti\u0107 M, Jelen\u010di\u0107 V, Lemmermann NAW, ten Brinke A, Jonji\u0107 S, et al. NKG2D induces Mcl-1 expression and mediates survival of CD8 memory T cell precursors via phosphatidylinositol 3-kinase. J Immunol. 2013;191:1307\u201315.","journal-title":"J Immunol"},{"key":"825_CR101","first-page":"1","volume":"14","author":"K Prajapati","year":"2018","unstructured":"Prajapati K, Perez C, Rojas LBP, Burke B, Guevara-Patino JA. Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy. Cell Mol Immunol. 2018;14:1\u201310.","journal-title":"Cell Mol Immunol"},{"key":"825_CR102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0531-2","volume":"7","author":"C Perez","year":"2019","unstructured":"Perez C, Prajapati K, Burke B, Plaza-Rojas L, Zeleznik-Le NJ, Guevara-Patino JA. NKG2D signaling certifies effector CD8 T cells for memory formation. J Immunother Cancer. 2019;7:1\u201314.","journal-title":"J Immunother Cancer"},{"key":"825_CR103","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1111\/1759-7714.13650","volume":"11","author":"T Ota","year":"2020","unstructured":"Ota T, Fukui T, Nakahara Y, Takeda T, Uchino J, Mouri T, et al. Serum immune modulators during the first cycle of anti-PD-1 antibody therapy in non-small cell lung cancer: perforin as a biomarker. Thorac Cancer. 2020;11:3223\u201333.","journal-title":"Thorac Cancer"},{"key":"825_CR104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5812\/hepatmon.11903","volume":"13","author":"M Mahdavi","year":"2013","unstructured":"Mahdavi M, Amirrasouli H, Alavian SM, Behnava B, Kazerouni F, Keshvari M, et al. Impact of pegylated interferon-alfa-2a on perforin level in patients with chronic hepatitis B; preliminary study. Hepat Mon. 2013;13:1\u20135.","journal-title":"Hepat Mon"},{"key":"825_CR105","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4269\/ajtmh.23-0269","volume":"109","author":"S Ryu","year":"2023","unstructured":"Ryu S, Choi JK, Achangwa C, Cho S, Hwang J-H, Hwang J-H, et al. Temporal dynamics of serum perforin and granzymes in three different clinical stages of virus-induced severe fever with thrombocytopenia syndrome. Am J Trop Med Hyg. 2023;109:554\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"825_CR106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/sciadv.1400121","volume":"1","author":"M Hornig","year":"2015","unstructured":"Hornig M, Montoya JG, Klimas NG, Levine S, Felsenstein D, Bateman L, et al. Distinct plasma immune signatures in ME\/CFS are present early in the course of illness. Sci Adv. 2015;1:1\u201310.","journal-title":"Sci Adv"},{"key":"825_CR107","first-page":"1","volume":"10","author":"M Mabrouk","year":"2025","unstructured":"Mabrouk M, Wahnou H, Merhi Y, Abou-Saleh H, Guessous F, Zaid Y. The role of soluble CD40L in autoimmune diseases. J Transl Autoimmun. 2025;10:1\u20138.","journal-title":"J Transl Autoimmun"},{"key":"825_CR108","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12272-020-01296-1","volume":"44","author":"D Anka Idrissi","year":"2021","unstructured":"Anka Idrissi D, Senhaji N, Aouiss A, Khalki L, Tijani Y, Zaid N, et al. IL-1 and CD40\/CD40L platelet complex: elements of induction of Crohn\u2019s disease and new therapeutic targets. Arch Pharm Res. 2021;44:117\u201332.","journal-title":"Arch Pharm Res."},{"key":"825_CR109","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneuroim.2017.01.024","volume":"305","author":"H Masuda","year":"2017","unstructured":"Masuda H, Mori M, Uchida T, Uzawa A, Ohtani R, Kuwabara S. Soluble CD40 ligand contributes to blood\u2013brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder. J Neuroimmunol. 2017;305:102\u20137.","journal-title":"J Neuroimmunol"}],"container-title":["Biology of Sex Differences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13293-026-00825-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13293-026-00825-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13293-026-00825-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:58:31Z","timestamp":1771423111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13293-026-00825-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["825"],"URL":"https:\/\/doi.org\/10.1186\/s13293-026-00825-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7642874\/v1","asserted-by":"object"}]},"ISSN":["2042-6410"],"issn-type":[{"value":"2042-6410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were approved by NOVA Medical School ethics committee (178\/2024\/CEFCM) and by ethics committee for health from ARSLVT (2508\/CES\/2023), in accordance with the provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonization. All the participants signed the informed consent at the time of enrolment in the study and completed the clinical survey.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants sign the informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}